Extended Data Fig. 2: Responder and non-responder CART-123 infusion products are similar.

a, Percentage of CD4 + CAR+ (left) or CD8 + CAR+ (right) populations expressing the indicated activation markers. b, Dot plot of t-distributed stochastic neighbor embedding (t-SNE) of CAR T products from all available patients (left). Distributions of cells from individual patients are labeled with patient ID (right). Red plots indicate initial partial (patient 10) or complete (patients 5 and 13) responses defined by day 14 bone marrow aspirate/biopsy. Blue plots indicate stable progressive disease on day 14 marrows. All analyzed patients are represented in two main populations. c, Percentage of CD4 + CAR+ (left) or CD8 + CAR+ (right) populations designated as naïve or stem cell memory (TN/TSCM), central memory (TCM), effector memory (TEM), or terminally differentiated effector memory (TEMRA) by CD45RA and CCR7 expression. d, Normal donor CART-123 (two independent replicates, black bars) and left-over infusion product from the indicated clinical trial subjects were incubated with an AML cell line (MOLM14) at a 1:5 effector:target ratio for 5 days. T cells were counted, and proliferation is represented as the fold-change in the MOLM14-stimulated CAR T cells compared with no stimulation control. Normal donor replicates are shown in black. Two of three subjects with early marrow blast reduction (UPN10, UPN13) were available and are shown in green. Four subjects with no change in marrow blasts (UPN 1, 12, 16, 20) are shown in yellow (note that UPN 1 blasts were 0% prior to CART-123 infusion and 0% at day 28 after CART-123 infusion). Five subjects with increase in marrow or blood blasts (UPN 2, 8, 9, 21 and 22) are shown in red. e, Correlation of fold expansion in vitro of subjects’ infusion products with their peak VCN when measured after infusion (expressed as copies/ug gDNA). Each circle represents an individual subject. Pearson r = -0.19, P = 0.57.